Clinical Outcomes of Serious Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 3, Randomized, Multi-National, Open-Label Trial of Meropenem-Vaborbactam (M-V) Vs. Best Available Therapy (BAT)

Zhang, Shu; Cornely, Oliver Andreas; Dudley, Michael N; Loutit, Jeffrey S; Alexander, Elizabeth M.; Daikos, George; Mathers, Amy; Vazquez, José Casas; Kaye, Keith S.

doi:10.1093/ofid/ofx163.1392

Record: found
Abstract: not found
Article: not found

Clinical Outcomes of Serious Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 3, Randomized, Multi-National, Open-Label Trial of Meropenem-Vaborbactam (M-V) Vs. Best Available Therapy (BAT)

Author(s): Keith S Kaye , Jose Vazquez , Amy Mathers , George Daikos , Elizabeth Alexander , Jeffrey S Loutit , Shu Zhang , Michael N Dudley , Oliver Cornely

Publication date Created: October 04 2017

Publication date (Electronic): October 04 2017

Journal: Open Forum Infectious Diseases

Publisher: Oxford University Press (OUP)

Read this article at

ScienceOpenPublisher

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

Title: Open Forum Infectious Diseases

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 2328-8957

Publication date Created: 2017

Publication date Created: October 01 2017

Publication date Created: October 04 2017

Publication date (Print): 2017

Publication date (Print): October 01 2017

Publication date (Electronic): October 04 2017

Volume: 4

Issue: suppl_1

Pages: S534-S535

Article

DOI: 10.1093/ofid/ofx163.1392

Product

Self URI (article page): http://academic.oup.com/ofid/article/4/suppl_1/S534/4295881/Clinical-Outcomes-of-Serious-Infections-due-to

Data availability:

Clinical Outcomes of Serious Infections due to Carbapenem-Resistant Enterobacteriaceae (CRE) in TANGO II, a Phase 3, Randomized, Multi-National, Open-Label Trial of Meropenem-Vaborbactam (M-V) Vs. Best Available Therapy (BAT)

Read this article at

Related collections

International Journal of Materials Research (IJMR)

Author and article information

Journal

Article

Product

Comments

Comment on this article

Similar content 1,415

Cited by 6